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Abstract: Among the pharmaceutical options available for treatment of ovarian cancer, attention 
has been increasingly focused on trabectedin (ET-743), a drug which displays a unique mecha-
nism of action and has been shown to be active in several human malignancies. Currently, single 
agent trabectedin is approved for treatment of patients with advanced soft tissue sarcoma after 
failure of anthracyclines and ifosfamide, and in association with pegylated liposomal doxoru-
bicin for treatment of patients with relapsed partially platinum-sensitive ovarian cancer. This 
review aims at summarizing the available evidence about the clinical role of trabectedin in the 
management of patients with epithelial ovarian cancer. Novel perspectives coming from a better 
understanding of trabectedin mechanisms of action and definition of patients subgroups likely 
susceptible to benefit of trabectedin treatment are also presented.
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Introduction
Epithelial ovarian carcinoma is one of the most common gynecological malignancies, 
and the fifth most frequent cause of cancer death in women.1 The estimated numbers of 
new cases of ovarian cancer per year in the United States is 21,980, with an estimated 
number of deaths of 14,270.1,2
The standard of care for the management of ovarian cancer patients includes optimal 
cytoreduction (ie, residual tumor ,1 cm) followed by adjuvant chemotherapy with a 
platinum/taxane combination associated and followed by bevacizumab in advanced 
stage, high-risk patients.3–5 However, despite the advances in surgical efforts and the 
achievement of high response rates (70%–80%) to front-line treatment, ovarian cancer 
remains the most lethal gynecological malignancy, with 50%–75% of cases experi-
encing progression/recurrence of disease; indeed, the 5-year overall survival (OS) is 
around 25%–30% in advanced stage disease.1,2
The major determinants of clinical outcome have been represented for years by 
the extent of residual tumor at primary surgery and sensitivity to platinum-based 
therapy, the latter parameter being defined according to the duration of the platinum-
free interval (PFI).6 In the clinical setting, patients are considered platinum resistant 
if  progression/recurrence of disease occurs during chemotherapy or within 6 months 
from its completion; salvage single-agent chemotherapy with nonplatinum drugs has 
always resulted in short-lived response rates in approximately 10%–25% of patients,7 
until recent evidence showed that the addition of bevacizumab provides higher response 
rates and even prolongation of OS.8
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On the other hand, patients defined as platinum sensitive 
(those recurring/progressing after 6 months from the end of 
primary treatment) have been usually triaged to platinum-
based combinations,6 although this therapeutic paradigm has 
been modified by the increasingly relevant evidence from 
the OCEANS trial showing the advantage of combining the 
platinum-based regimen with bevacizumab as compared to 
the platinum-taxane regimen.9 In the context of the so-called 
platinum-sensitivity, relapse/progression within 6–12 months 
after the administration of primary chemotherapy  represents 
a sort of gray zone in terms of platinum resistance/
responsiveness, and this is strongly supported by the clini-
cal evidences that in this subset of patients, response rates 
range between 27% and 33% in patients administered either 
platinum-based rechallenge versus nonplatinum drugs.10
In this context, the optimal management of partially 
platinum-sensitive recurrent ovarian cancer patients still 
remains to be firmly defined; indeed, based on preclinical 
and retrospective studies, it has been proposed that prolon-
gation of PFI through the administration of platinum agents 
could result in a higher response rate to subsequent platinum 
rechallenge.11,12 This hypothesis represents the rationale sus-
taining the setup of prospective Phase III randomized trials 
aimed at verifying whether prolongation of PFI through the 
use of nonplatinum agents could result in a higher response 
rate and better clinical outcome compared to the immedi-
ate rechallenge with platinum-based regimens in partially 
platinum-sensitive recurrent ovarian cancer patients.
Overall, these results highlight the need to clarify the ther-
apeutic scenario for each clinical setting in order to optimize 
any drug or drug combination therapeutic performances.
In this context, among the pharmaceutical options 
 currently available in the armamentarium of medical 
treatment of ovarian cancer, much emphasis has been pro-
gressively placed on trabectedin (ET-743, Yondelis®; Zeltia, 
Madrid, Spain, and Johnson & Johnson, New Brunswick, 
New Jersey, USA), which had gained much attention because 
of its unique mechanism of action and the demonstration 
of clinical activity in ovarian cancer as well as other solid 
malignancies.13–16
Since 2007, trabectedin represents the first anticancer 
marine-derived drug that has obtained marketing authoriza-
tion from the European Medicines Agency (EMA), and in 
many other countries worldwide for treatment of patients with 
advanced soft tissue sarcoma after failure of anthracyclines 
and ifosfamide, or for those patients who are unsuitable to 
receive these agents. Moreover, based on the reported results 
of OVA-301 Phase III randomized study,16 in 2009 EMEA 
granted marketing authorization for trabectedin combined 
with pegylated liposomal doxorubicin (PLD) for treatment 
of patients with relapsed partially platinum-sensitive ovar-
ian cancer.17 This review will focus on the clinical role of 
trabectedin in the management of patients with epithelial 
ovarian cancer. A brief overview of the process of trabectedin 
development, as well as the new perspectives of trabectedin 
employment, will also be provided.
Trabectedin structure  
and mechanisms of action
Trabectedin is a marine-derived tetrahydroisoquinoline 
alkaloid with antitumor activity, originally isolated from the 
tunicate Ecteinaiscidia turbinata and currently synthetically 
produced.18 As shown in Figure 1, trabectedin is constituted 
by a pentacyclic backbone composed of two fused tetra-
hydroisochinoline rings linked to a ten-membered lactone 
bridge through a benzylic sulfide linkage and attached to an 
additional ring system.
Several studies have proposed that the mechanism 
of action of this compound is more complex than those 
exerted by conventional cytotoxic agents: in particular, 
its peculiar structure might allow the drug to interact with 
DNA through a covalent binding at the N2-guanine at the 
minor DNA groove, and also to protrude outside of the DNA 
helix, thus being available to bind several DNA-binding 
molecules such as transcriptional factors and DNA repair 
proteins.19,20 Binding to the minor DNA groove induces 
a bend of the helix toward the major groove and a DNA 
damage; this is recognized by the nucleotide excision repair 
(NER) system, and results in the accumulation of ternary 
DNA-trabectedin–protein repair complexes which lead, 
after collision with the replication fork, to the formation of 
double-strand DNA breaks, block of cell cycle, and induc-
tion of p53-independent apoptosis.21–24 These findings sup-
port the demonstration that, contrary to what is known for 
other DNA-binding agents, a functional NER system seems 
required for efficient trabectedin cytotoxicity; in fact, it has 
been shown that Chinese hamster and human ovarian cell 
lines deficient for genes essential for NER system activity, 
such as xeroderma pigmentosum, complementation group A, 
B, D, F and G (XPA, XPB, XPD, XPF, XPG), and excision 
repair cross-complementation 1 (ERCC1), are resistant to 
trabectedin, and this resistance is reverted by complementa-
tion of the cells with the corresponding gene.21,25
On the other hand, trabectedin is expected to be more 
effective in cells lacking functional homologous recom-
binant repair (HRR) mechanisms, such as those endowed 
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with BReast CAncer (BRCA) gene mutation or BRCAness 
phenotype: preclinical data confirm that, besides the require-
ment of a functional transcription coupled NER machinery, 
a deficient HRR system is also needed for in vitro sensitivity 
to trabectedin.22
A retrospective analysis conducted in a cohort of 
 paraffin-embedded tumor tissues from sarcoma patients 
treated with trabectedin as rescue therapy showed a correla-
tion between low tumor BRCA1 messenger ribonucleic acid 
(mRNA) expression levels and both a higher percentage of 
patients free of disease progression at 6 months (33% versus 
11%, P=0.02), and a longer median OS (15 months versus 
5 months, P=0.0003) compared to patients with high tumor 
BRCA1 mRNA expression levels.26 Taken together, all these 
observations support the hypothesis that sensitivity to tra-
bectedin correlates with functional NER and deficient HRR 
systems, features that can be exploited for optimal manage-
ment of specific settings of patients.
Besides these direct effects on the DNA helix, trabectedin 
is able to interfere with transcription regulatory pathways 
in a promoter- and gene-dependent manner, as well as in a 
cell-dependent fashion; in particular, trabectedin has been 
shown to inhibit binding of transcription factors to DNA, 
thus blocking their transactivating effects. This has been 
reported in myxoid/round cell liposarcoma xenograft models 
in which therapeutic doses of trabectedin led to a detach-
ment of the abnormal fusion protein FUS-CHOP from its 
promoters; this phenomenon translates into an improved 
drug sensitivity which becomes higher as far as the block 
of the transactivating activity of FUS-CHOP is prolonged.27 
This area of research is getting more and more attention not 
only because it can provide novel information for a deeper 
understanding of the pleiotropic activity of trabectedin, but 
also because it might help defining the clinical settings most 
suitable to benefit of this peculiar drug.
Besides disrupting DNA function and interfering with 
transcription regulatory pathways, very recent studies have 
also highlighted that trabectedin could exert its antitumor 
activity by targeting some normal host cells. In particular, 
 trabectedin has been shown to selectively deplete blood 
monocytes and tumor-associated macrophages in tumor-
bearing mice as well as in tissue biopsies from soft tissue 
sarcoma and ovarian cancer patients.28–30 This selective 
effect seems to be ascribed to the ability of trabectedin to 
rapidly trigger the activation of Caspase 8 downstream of 
the TNF-related apoptosis-inducing ligand (TRAIL) mem-
brane receptor, which is highly expressed in monocytes and 
macrophages compared to lymphocytes and neutrophils.29,30 
Indeed, tumor-associated macrophages play a major role 
in the production of growth factors (ie, epidermal growth 
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Figure 1 Schematic picture of the unique and complex mechanism of action of trabectedin.
Abbreviations: eGF, epidermal growth factor; veGF, vascular endothelial growth factor.
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factor, chemokines, interleukins, metalloproteinases, and 
vascular endothelial growth factor), which promote tumor 
cell survival and metastatic phenotype. The demonstration 
that trabectedin was effective in a trabectedin-resistant in 
vivo model, while being not effective in the same cancer cell 
lines in vitro, clearly showed that the specific trabectedin-
induced tumor cytotoxicity on circulating monocytes and 
macrophages could be involved in antitumor activity, and that 
part of antitumor activity of the drug could be ascribed to its 
ability to act as a tumor microenvironment modifier.
Overall, trabectedin can be considered more than a 
cytotoxic drug on the basis of the combination of multiple 
mechanisms of action, which provide the chance for a more 
multifaceted activity than initially formulated. Through 
these mechanisms trabectedin is likely to impact on relevant 
biological pathways involved in cancer biology, which may 
influence disease outcome.
Trabectedin pharmacokinetic 
features and Phase I studies
Trabectedin shows a high plasma protein binding (94%–
98%), and a longer terminal half-life; in a population 
pharmacokinetic review on single agent trabectedin admin-
istered according to different schedules, the terminal  half-life 
resulted at around 180 hours.31 Moreover, the distribution 
volume at steady state was generally reported to be large 
(up to 4,000 L) in the weekly administration as well as in the 
3-weekly schedules.32–39
Trabectedin is metabolized in the liver mainly by the 
CYP3A4 enzyme, but also through the CYPC29, CYP2C19, 
and CYP2D6 isoenzymes and glutathione  transferases.40 The 
major involvement of CYP3A4 isoenzyme in trabectedin 
metabolism in vivo may have some clinical implications. 
The interaction between trabectedin and pharmaceutical 
agents which share the same metabolic pathway cannot be 
excluded;41 moreover, the consequences of the higher levels 
and faster conversion performances of CYP3A4 in female 
human microsomes have to be taken into account.42 At the 
end, almost 60% of the drug is eliminated in the feces and 
only 6% in the urine.43,44
Table 1 summarizes the studies investigating the safety 
and assessing the maximum tolerated dose (MTD) for trabect-
edin used as single agent;32–39 different dose escalation and 
schedules have been explored, including 3-weekly schedules 
(1 day, 1-hour to 72-hour infusion; 5 consecutive days, 1-hour 
infusion), or every 4 weeks schedule (1 day, 1-hour to 3-hour 
infusion) (Table 1).
Neutropenia and thrombocytopenia were reported as the 
most frequent dose-limiting toxicities (DLT). Hepatotoxicity 
consisted mainly of elevation of transaminases; this toxicity 
was consistently reported to increase with trabectedin area 
under the curve (AUC), although it was always reversible 
(duration between 3–4 weeks), and not dose limiting.32 
Moreover, hepatotoxicity was even lower when the dose 
was divided over 5 days compared to the single-dose 
schedule.37
Table 1 Phase i studies with trabectedin as single agent
First author Type of tumor Schedule Doses MTD RD DLTs
Forouzesh  
(2009)32
Solid tumors 4-weekly 
•  1-h weekly for  
3 weeks
•  3-h weekly for  
3 weeks
0.46 to 0.80 mg/m2 
0.30 to 0.65 mg/m2
0.70 mg/m2 
0.65 mg/m2
0.61 mg/m2 
0.58 mg/m2
Neutropenia 
elevation of 
transaminases
van Kesteren  
(2000)33
Solid tumors 3-weekly 
• 24-h infusion
0.05–1.8 mg/m2 1.8 mg/m2 1.5 mg/m2 Neutropenia 
Thrombocytopenia
van Kesteren  
(2002)34
Solid tumors 3-weekly 
• 1-h infusion
0.05–1.1 mg/m2 1.8 mg/m2 1.5 mg/m2 Neutropenia 
Thrombocytopenia
Taamma (2001)35 Solid tumors 3-weekly 
• 24-h infusion
0.05–1.8 mg/m2 1.8 mg/m2 1.5 mg/m2 Neutropenia 
Thrombocytopenia
Ryan (2001)36 Solid tumors 3-weekly 
• 72-h infusion
0.06 to 1.2 mg/m2 1.2 mg/m2 1.05 mg/m2 Hematologic
villalona-Calero 
(2002)37
Solid tumors 3-weekly 
• 1-h daily for 5 days
0.06 to 0.038 mg/m2/d 0.325 mg/m2/d 0.325 mg/m2/d Neutropenia
Twelves (2003)38 Solid tumors 3-weekly 
• 1-h infusion
• 3-h infusion
 
0.05 to 1.1 mg/m2
1.1 mg/m2 
1.8 mg/m2
1.0 mg/m2 
1.65 mg/m2
Neutropenia 
Thrombocytopenia 
Fatigue
Pardo (2012)39 Solid tumors 3-weekly 
• 3-h infusion
0.75 to 1.3 mg/m2 1.3 mg/m2 1.5 mg/m2 Neutropenia
Abbreviations: d, day; DLT, dose-limiting toxicity; h, hour; MTD, maximum tolerated dose; RD, recommended dose.
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Escalation of trabectedin was also investigated in patients 
with alteration of hepatic function stratified according to the 
basal levels of alkaline phosphatase (AP); MTD was defined 
only in the subgroup of cases with AP between normal 
and #1.5 mg/m2, and results equivalent to 1.3 mg/m2, while 
there were critical issues in full enrollment of patients with 
more elevated AP level. Interestingly enough, there was no 
difference in serum level of markers of liver function (bili-
rubin, transaminases, etc) according to different serum AP 
levels;39 this finding has been confirmed in a pharmacokinetic 
analysis in which no relation was evident between AP or 
transaminase levels with trabectedin pharmacokinetics.31 
In conclusion, as far as the available data are concerned, 
 trabectedin (at the dose of 1.3 mg/m2) can be utilized in 
patients with mild hepatic dysfunction, who nevertheless 
should be closely monitored.39
A summary of the Phase I studies with trabectedin in 
combination is provided in Table 2. The rationale for explor-
ing the combination of trabectedin with platinum compounds 
relies on the available evidences about the molecular target 
of the two drugs. Platinum agents hit the major groove of 
DNA, thus inducing DNA damage which is repaired by 
the HRR system. On the other hand, trabectedin activity 
requires an efficient NER machinery.23,25 Moreover, earlier 
preclinical studies have demonstrated a synergistic effect of 
the combination.45 In 2009, Sessa et al46 published a Phase I 
study investigating cisplatin (40 mg/m2, Days 1 and 8, every 
21 days) combined with escalating dose of trabectedin (from 
0.3 to 0.7 mg/m2); 39 patients were treated in the dose-
finding step, and ten patients were enrolled in the expansion 
part of the study. MTD of trabectedin was 0.7 mg/m2, with 
neutropenia representing the most common DLT, while the 
recommended doses (RD) were 0.5 mg/m2 and 0.6 mg/m2 
in the previously treated and naïve patients, respectively. 
Other toxicities were represented by nausea/vomiting (67%), 
 asthenia/fatigue (55%), and reversible transaminases eleva-
tion (51%). Confirmed partial responses were reported in four 
of 13 evaluable ovarian cancer patients, and in one patient 
with uterine leiomyosarcoma.46 Since the 3-weekly adminis-
tration was considered to be responsible for a higher neutro-
penia and liver toxicity, a Phase I study utilizing the 3-weekly 
schedule was planned47; the regimen consisted of cisplatin at 
a fixed dose of 75 mg/m2, 1-hour intravenous infusion, fol-
lowed by escalating doses of trabectedin in a 3-hour infusion, 
with both drugs administered on day 1. Two DLTs, grade 4 
neutropenia longer than 7 days duration and grade 3 vomiting 
despite standard antiemetic therapy, occurred at the starting 
dose of trabectedin (0.75 mg/m2); therefore, the immediately 
lower dose (trabectedin 0.60 mg/m2) was evaluated in a total 
of eight patients. No DLTs occurred, and this was declared the 
recommended dose. Two out of five ovarian cancer patients 
experienced partial response to treatment (response rate, 
17.0%; lasting 4.1 and 8.4 months, respectively), and it is 
worth noting that five patients had stable disease (including 
sarcoma, ovarian and breast cancer patients). These results, 
which are comparable to those obtained with the weekly 
schedule, and also with results from the Phase I study 
 utilizing trabectedin combined with carboplatin, showed 
that the 3-weekly schedule is feasible, tolerable, and able to 
produce some antitumor activity.
The combination trabectedin-carboplatin was investi-
gated in a Phase I study focused on the two different clini-
cal settings:48 carboplatin-pretreated patients who received 
carboplatin AUC 4 (Group 1) and carboplatin-naïve patients 
who received carboplatin AUC 5 (Group 2), both as a 1-hour 
infusion followed by trabectedin at the dose range from 
0.5–1.2 mg/m2 in the 3-weekly schedule. A total of 44 patients 
were enrolled and treated: in Group 1 (N=18), at the trabect-
edin dose of 1.0 mg/m2, only one out of ten patients had DLTs; 
however, given the high frequency of dose delays which 
resulted in 66.7% of rescheduling, the recommended dose 
was established to be 0.8 mg/m2  combined with  carboplatin 
AUC 4. In Group 2, DLTs occurred at trabectedin 0.8 mg/m2 
(3/8 patients), 1.0 mg/m2 (3/10 patients), and 1.2 mg/m2 (2/2 
patients) with cumulative hematological toxicity associated 
with an important number of transfusions. In this group, 
neither the MTD nor the RD were established, thus requiring 
further investigation. Promising antitumor activity was found 
for this combination, especially in patients with advanced 
ovarian cancer and soft tissue sarcoma. In particular, in 
Group 1 patients, two partial responses and six stable disease 
were documented, while in Group 2 there were two partial 
responses and 14 stable disease.
One of the most promising trabectedin combinations is 
represented by the association with PLD: indeed, in vitro 
and in vivo studies had earlier suggested an additive or even 
a weak synergism between the two drugs according to type 
of experimental models.49 The combination of trabectedin 
plus PLD has been investigated in a Phase I study including 
36 patients. Patients were administered PLD (30 mg/m2, 
1-hour infusion), followed by one of the six trabectedin 
doses (0.4, 0.6, 0.75, 0.9, 1.1 and 1.3 mg/m2) infused over 
3 hours and repeated every 21 days until evidence of complete 
response, disease progression, or unacceptable toxicity.50 The 
MTD of trabectedin was 1.1 mg/m2. Neither drug had its 
PK affected by concomitant administration compared with 
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trabectedin and PLD each given as a single agent. The most 
common grade 3–4 toxicities were neutropenia (31%) and 
elevated transaminases (31%). Six patients responded (one 
complete response, five partial responses), with an objective 
response rate of 16.7%, and 14 patients (39.0%) have had 
stable disease for more than 4 months, including two out of 
four ovarian cancer patients enrolled.
As far as combination of paclitaxel and trabectedin is 
concerned, some earlier evidences from preclinical studies 
had already shown that the two drugs were able to exert a 
sequence-dependent synergistic cytotoxicity in sarcoma 
and breast cancer cells in vitro,51,52 and an additive effect 
in breast cancer xenografts.52 The Phase I study published 
by Chu et al53 investigated dose escalation of  trabectedin 
(0.525–0.775 mg/m2, 3-hour infusion) plus paclitaxel 
(80–120 mg/m2), every 14 days. As expected, neutropenia 
was the main DLT. At the doses of paclitaxel 120 mg/m2, and 
trabectedin 0.65 mg/m2, there was only one DLT in eleven 
patients; however, given the long-lasting grade 4 neutropenia 
and the long recovery time, these doses were considered as 
the RD. As far as antitumor activity is concerned, response 
was seen in only one patient, but there were ten cases of stable 
disease which lasted .10 months in five patients.
Trabectedin and gemcitabine were administered on 
Day 1, 8, and 15 of a 28-day cycle at planned doses of 
0.3–0.58 mg/m2 and 800–1,000 mg/m2 in the Phase I study 
by Messersmith et al54 There were no DLTs with trabectedin 
0.4 mg/m2 and gemcitabine 1,000 mg/m2; however, the high 
frequency of dose modifications (reduction, delay) limited the 
determination of MTD for the weekly schedule, thus solicit-
ing an alternative schedule of treatment. Finally, the Phase I 
study by Gore et al55 investigated trabectedin (0.4–1.3 mg/m2) 
and capecitabine (2,000 mg/m2/day orally every 3 weeks). 
Since gastrointestinal DLT toxicity were documented with 
2,000 mg/m2/day capecitabine, the dose was reduced to 
1,600 mg/m2/day, and escalation of trabectedin was started 
at 0.6 mg/m2. MTD resulted at 1,600 mg/m2/day plus tra-
bectedin 1.1 mg/m2. No pharmacokinetic interaction was 
documented between the two drugs. One patient had partial 
response, while 18 patients had long-lasting stable disease.
Overall, the combination of trabectedin with the most 
commonly used agent in ovarian cancer was demonstrated 
to be feasible and endowed with some antitumor activity. 
None of the described combinations showed an influence 
of each of the two drugs as far as pharmacokinetic features 
are concerned.
Phase II studies with trabectedin  
as single agent or in combination
A summary of Phase II studies using trabectedin as a 
single agent in ovarian cancer56–58 is presented in Table 
3. When considering the whole series in each study, the 
response rate ranges between 16.3% and 38.9%, although 
the relatively high patient heterogeneity likely represents a 
major limit for reliable comparisons. Indeed, the percent-
age of patients already administered up to two previous 
lines of chemotherapy ranged between 28.3% and 40.7%. 
More importantly, the rate of cases defined as bearing 
platinum-resistant versus platinum-sensitive disease 
largely differed across the studies; in particular, the frac-
tion of platinum- resistant patients ranged between 3.8% 
up to 55.0%. Therefore, a more reliable analysis of results 
should focus on specific clinical settings. In the subgroup 
of platinum-resistant patients, the rate of response was, as 
expected, low (range: 6.3%–7.0%), while in patients with 
platinum-sensitive disease, trabectedin was able to induce 
Table 3 Phase ii studies with trabectedin single agent or in combination
First author Type of 
study
Patients 
(No)
Dose, schedule Patients with 
#2 previous 
lines (%)
Platinum 
resistant 
patients (%)
Response 
rate (%)
Median 
PFS (mts)
Median 
OS (mts)
Sessa  
(2005)56
Phase ii All 59 
Res 19 
Sen 30
1.3 mg/m2, q21-d 37 32.0 All 22 
Res 7 
Sen 43
na na
Krasner57  
(2007)
Phase ii All 147 
Res 81 
Sen 66
0.58 mg/m2,  
(3-h), weekly for 
3 weeks, q28-d
All 31 
Res 35 
Sen 26
55.0 All 16.3 
Res 6.3 
Sen 29.0
 
2.0 
5.1
 
11.1 
nr
Del Campo 
(2009)58
Randomized 
Phase ii
Arm 1 55 
Arm 2 53
1.5 mg/m2 (24-h), 
q21-d versus 
1.3 mg/m2 (3-h),  
q21-d
40.7 
28.3
9.2 
3.8
Arm 1 38.9 
Arm 2 35.8
6.1 
6.8
na
Abbreviations: h, hours; mts, months; na, not available; No, number; nr, not reached; OS, overall survival; PFS, progression-free survival; q, every; Res, platinum-resistant; 
Sen, platinum-sensitive.
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objective response between 29.0% and 43.0%. A pooled 
analysis of the available Phase II studies59 reported an objec-
tive response rate of 26.0%, a median duration of response of 
5.5 months, and a very encouraging rate of stable disease in 
almost 30% of cases. Interestingly enough, patients adminis-
tered the 3-weekly schedule exhibited a higher response rate 
 compared to cases administered the weekly regimen (36.0% 
versus 16.0%, P=0.0001). Finally, it has to be emphasized 
that trabectedin activity does not seem to be related to the 
amount of previous chemotherapy lines. In this context, 
a recently published large, retrospective study on 98 heavily 
treated recurrent ovarian cancer patients (median number of 
previous treatments: 4) reported an objective response rate 
of 27.5%, a rate which did not vary according to number 
of previously administered chemotherapy lines.60 In the 
pooled analysis of data relative to the 3-weekly regimens, 
median progression-free survival (PFS) was calculated to 
be 5.6 months with both the 24-hour and the 3-hour infu-
sions; on the other hand, median PFS was only 2.8 months in 
patients treated with the weekly schedule.59 This difference 
was also documented for OS; indeed, median OS was longer 
for the 3-weekly 24-hour infusion (median OS: 20.4 months) 
and the 3-hour infusion (median OS: 17.1 months) compared 
to the weekly schedule (median OS: 13.7 months).59
As far as toxicity is concerned, reversible myelosup-
pression and transient elevation of transaminases were the 
most frequent hematological and nonhematological toxici-
ties, respectively, regardless of the schedule of  trabectedin 
administration (Table 4). In particular, grade 3–4  neutropenia 
was registered in 26% of patients from the pooled analysis 
of the three Phase II studies, while grade 3–4 elevation 
of AST and ALT was reported in 18% and 38% of cases, 
respectively.
Overall, all Phase II studies highlighted the promising 
activity of trabectedin single agent, especially in patients 
with platinum-sensitive disease, as well as a manageable and 
noncumulative toxicity profile of the drug.
Trabectedin: Phase III studies
Based on the strong rationale sustaining the association 
trabectedin/PLD and the favorable results from preclinical 
and Phase I studies, this combination was chosen for the 
direct comparison with PLD in the Phase III trial OVA-
301 (NCT00113607). This study, planned in 2005, aimed 
at comparing trabectedin 1.1 mg/m2/PLD 30 mg/m2 every 
21 days versus PLD 50 mg/m2 every 28 days in ovarian, 
peritoneal, and tubal cancer recurring/progressing after first-
line chemotherapy,61 with the exclusion of refractory cases; 
patients were stratified according to the Eastern Cooperative 
Oncology Group Performance Status (0–1 versus 2) and 
platinum sensitivity (PFI ,6 months versus PFI $6 months). 
Originally, the primary endpoint was OS, but it was later 
amended to PFS at the end of 2006. Secondary endpoints 
included response rates, duration of response, safety, and 
quality of life issues. Overall, 672 patients were enrolled 
(337 allocated to trabectedin/PLD versus 335 allocated to 
PLD). In the whole series, the response rate, as assessed 
by independent radiology review by RECIST (Response 
Evaluation Criteria in Solid Tumors), was significantly higher 
in trabectedin/PLD than PLD alone group (27.6% versus 
18.8%, P=0.008). In platinum-resistant cases (n=242), no 
difference in response rate was observed in the combina-
tion versus PLD alone (13.4% versus 12.2%, respectively), 
while platinum-sensitive patients showed a higher response 
rate to trabectedin/PLD compared to PLD (35.3% versus 
22.6%; P=0.0042).
Median PFS was 7.3 months for the combination arm 
and 5.8 months for the single agent arm, with a hazard ratio 
(HR) of 0.79 (95% confidence interval [CI]: 0.65–0.96; 
P=0.019). There was no difference in median PFS between 
the two arms in the platinum-resistant population; on the 
other hand,  superiority of trabectedin/PLD versus PLD alone 
was shown in  platinum-sensitive disease, since median PFS 
was 9.2 months versus 7.5 months, respectively, with a HR 
of 0.73 (95% CI: 0.56–0.95; P=0.017).
Table 4 Toxicity from Phase ii studies with trabectedin single agent or in combination
First author Dose, schedule Neutropenia  
(%)
Thrombocytopenia  
(%)
Elevation of  
AST (%)
Elevation 
of ALT (%)
Fatigue 
(%)
Sessa 
(2005)56
1.3 mg/m2, q21-d 41 7 75a – 7
Krasner 
(2007)57
0.58 mg/m2, (infusion 3-h),  
weekly for 3 weeks, q28-d
8 3 3 12 5
Del Campo 
(2009)58
1.5 mg/m2 (infusion 24-h), 
q21-d versus 1.3 mg/m2 
(infusion 3-h), q21-d
54 
38
8 
10
35 
19
56 
58
15 
8
Note: aFrom grouped data about AST and ALT.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; h, hours; q, every.
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When analysis of PFS was performed in the subgroup of 
partially platinum-sensitive disease (N=214), the superiority 
of trabectedin/PLD versus the single agent was even more 
evident: median PFS was 7.4 versus 5.5 months, respectively; 
the HR was 0.65 (95% CI: 0.45–0.92; P=0.0152), which 
translated into a 35% reduction of progression of disease.62 
Since then, however, it has become evident that an imbalance 
in the duration of PFI in favor of the PLD arm could have 
influenced outcome results. Mature data about OS have been 
published in 2012.63
After a median follow up of 47.4 months, 522 deaths 
were registered in the entire population: median OS was 
22.2 months for trabectedin/PLD versus 18.9 months in 
PLD-treated patients, with a HR of 0.86 (95% CI: 0.72–1.02; 
P=0.0835).
However, subsequent analysis adjusting for PFI duration 
was performed and a statistically significant improvement of 
OS was shown favoring trabectedin/PLD with a HR of 0.82 
(95% CI: 0.69–0.98; P=0.0285). Overall, in platinum-sensi-
tive recurrent ovarian cancer patients there was no statistically 
significant difference according to treatment (median OS of 
27 months for combination versus 24.2 months for single 
agent; HR: 0.83, 95% CI: 0.67–1.04, P=0.105).  However, 
an additional unplanned exploratory analysis showed that 
patients with a PFI between 6–12 months showed the largest 
OS benefit from the combination, with a HR of 0.64 (95% 
CI: 0.47–0.86; P=0.0027).63
The selective superiority of trabectedin/PLD in the subset 
of partially platinum-sensitive patients could not be ascribed 
to the number of treatments administered after progression on 
the OVA-301 study: indeed, the percentage of patients 
receiving subsequent treatment after progression during the 
OVA-301 study was similar between the two arms (76% 
versus 77% for combination versus single agent arm); 
platinum-based regimens were less frequently administered 
to patients progressing after trabectedin/PLD than PLD (48% 
versus 55%). On the other hand, it was shown that median OS 
from the administration of subsequent platinum-based che-
motherapy was longer in partially platinum-sensitive patients 
allocated to the trabectedin/PLD arm compared to those 
allocated to the PLD arm (median OS 13.3 months versus 
9.8 months, respectively, HR: 0.63, P=0.0357),  suggesting 
that the enhanced OS benefit with trabectedin/PLD compared 
to single agent PLD might be related to the prolongation 
of PFI.64 This hypothesis has fuelled the setup of Phase III 
randomized studies aiming at clarifying whether the artificial 
prolongation of PFI with a nonplatinum drug may improve the 
effectiveness of the overall treatment in patients with a PFI 
of 6–12 months after completion of primary  chemotherapy. 
In particular, the MITO-8 study (NCT00657878) randomizes 
patients to the combination carboplatin/paclitaxel versus 
PLD or topotecan or gemcitabine) and implies a crossover 
for both arms at disease progression. On the other hand, the 
Inovatyon (International Ovarian Cancer Patients Trial With 
Yondelis) study (NCT01379989) investigates the superiority 
of trabectedin/PLD versus carboplatin/PLD in partially 
platinum-sensitive disease.
As far as toxicity issues are concerned, Grade 3/4  anemia, 
neutropenia, and thrombocytopenia were documented in 
14%, 63%, and 18% of trabectedin/PLD cases, and were 
significantly more frequent compared to PLD alone. Among 
nonhematological toxicities, Grade 3/4 elevation of sGOT 
and sGPT was reported in 38% of cases, but it was described 
as of short duration, and of decreased magnitude with sub-
sequent cycles. On the other hand, hand and foot syndrome 
was documented in only 4% of cases in the combination 
arm compared to 20% in the PLD alone arm. In spite of 
the increased hematological toxicity in the trabectedin/PLD 
group, there was no deterioration of QoL/patient-reported 
outcome, as well as in QLQ-C30, OV28, and EQ-5D 
questionnaires.65 Moreover, a very recent cost-effectiveness 
analysis based on the final survival data of the OVA-301 
study confirmed a significant improvement of OS, and an 
increased cost-effectiveness ratio per quality-adjusted life-
year compared to the original evaluation.66 Based on these 
results, trabectedin/PLD combination can be considered as 
the most effective nonplatinum-based combination in par-
tially platinum-sensitive disease; this combination can be 
exploited not only to artificially prolong PFI with the aim to 
increase sensitivity to subsequent platinum treatment, but also 
to provide patients with an equivalent therapeutic alternative 
to platinum agents in case of residual neurotoxicity, history 
of platinum hypersensitivity, or repeated treatments with 
platinum regimens.
While awaiting for the identification of biomarkers predic-
tive of trabectedin sensitivity,67 other specific ovarian cancer 
clinical settings more likely to benefit from trabectedin or 
trabectedin combinations are actively investigated; given the 
strong rationale sustaining the role of BRCA 1/2 mutation or 
BRCAness in conditioning responsiveness to trabectedin, the 
MITO-15 (Multicenter Italian Trials in Ovarian Cancer and 
Gynecology) study (NCT01772979) has been conducted to 
investigate the efficacy of single agent  trabectedin in relapsed 
ovarian cancer with BRCA mutation or  exhibiting the BRCA-
ness phenotype. The trial has recently closed patient accrual, 
and analysis of data is ongoing. Finally, considering the recent 
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introduction of bevacizumab in the first-line treatment, and 
the upcoming approval in the salvage setting, there is increas-
ing interest in exploiting the  combination of trabectedin with 
the antiangiogenetic drug. In this context, a Phase II study 
(NCT01735071) has been recently launched aimed at assess-
ing the efficacy and safety of the combination trabectedin 
and bevacizumab with or without carboplatin in partially 
platinum-sensitive recurrent ovarian cancer patients.
Conclusion
Since its approval for treatment of partially platinum- sensitive 
recurrent disease, trabectedin has shown its potential for 
therapeutic exploitation in ovarian cancer; in particular, its 
peculiar mechanisms of action suggest its potential activity 
in specific subsets of ovarian cancer patients endowed with 
BRCA mutation or the so-called BRCAness phenotype 
(ie, serous, high-grade carcinomas; repeated response to 
 platinum-based regimens); this is likely to enlarge in the 
future the clinical settings in which candidates can take 
advantage of even single agent trabectedin. Moreover, the 
acquisition of recent evidences supporting the efficacy of 
trabectedin in modulating tumor microenvironment opens 
new potential scenarios for combinations with agents directed 
against angiogenesis as well as molecules involved in mac-
rophage activity.
Active search is ongoing in order to define biomarkers 
predictive of response to trabectedin treatment, and also 
to help clarify the biological mechanisms sustaining one 
of the special features of trabectedin activity, namely the 
 achievement of long-lasting stable disease.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Siegel R, MA J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 
2014;64(1):9–29.
2. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. 
Relative influences of tumor volume before surgery and the cytoreduc-
tive outcome on survival for patients with advanced ovarian cancer: 
a prospective study. Gynecol Oncol. 2003;90(2):390–396.
3. Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A. Systemic 
therapy in recurrent ovarian cancer: current treatment options and new 
drugs. Expert Rev Anticancer Ther. 2010;10(1):81–88.
4. Burger RA, Brady MF, Bookman MA, et al; Gynecologic Oncology 
Group. Incorporation of bevacizumab in the primary treatment of ovarian 
cancer. N Engl J Med. 2011;365(26):2473–2483.
5. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab 
in ovarian cancer. N Engl J Med. 2011;365(26):2484–2496.
6. Pujade-Lauraine E. How to approach patients in relapse. Ann Oncol. 
2012;23 Suppl 10:x128–x131.
7. Naumann RW, Coleman RL. Management strategies for recurrent 
platinum-resistant ovarian cancer. Drugs. 2011;71(11):1397–1412.
 8. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined 
with chemotherapy for platinum-resistant recurrent ovarian cancer: 
The AURELIA open-label randomized phase III trial. J Clin Oncol. 
2014;32(13):1302–1308.
 9. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, 
double-blind, placebo-controlled phase III trial of chemotherapy with 
or without bevacizumab in patients with platinum-sensitive recurrent 
epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin 
Oncol. 2012;30(17):2039–2045.
 10. Colombo N, Gore M. Treatment of recurrent ovarian cancer 
relapsing 6–12 months post platinum-based chemotherapy. Crit Rev 
Oncol Hematol. 2007;64(2):129–138.
 11. Bookman MA. Extending the platinum-free interval in recurrent ovarian 
cancer: the role of topotecan in second-line chemotherapy. Oncologist. 
1999;4(2):87–94.
 12. Pignata S, Ferrandina G, Scarfone G, et al; SOCRATES and MITO 
investigators. Extending the platinum-free interval with a non-platinum 
therapy in platinum-sensitive recurrent ovarian cancer. Results from the 
SOCRATES Retrospective Study. Oncology. 2006;71(5–6): 320–326.
 13. Vincenzi B, Napolitano A, Frezza AM, Schiavon G, Santini D, Tonini G. 
Wide-spectrum characterization of trabectedin: biology, clinical activity 
and future perspectives. Pharmacogenomics. 2010;11(6): 865–878.
 14. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of 
trabectedin in patients with advanced or metastatic liposarcoma or 
leiomyosarcoma after failure of prior anthracyclines and ifosfamide: 
results of a randomized phase II study of two different schedules. J Clin 
Oncol. 2009;27(25):4188–4196.
 15. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated 
liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: 
overall survival analysis. Eur J Cancer. 2012;48(15):2361–2368.
 16. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated 
liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 
2010;28(19):3107–3114.
 17. European Medicines Agency (EMA). Assessment Report for  Yondelis. 
International non-proprietary name/common name; Trabectedin 
procedure. No EMEA/H/C/000773/11/0008 [webpage on the Internet]. 
http://www.ema.europa.eu/humandocs/PDFs/EPAR/Yondelis/EMEA-
H-773-II-08-AR.pdf. 2009.
 18. Cuevas JC, Francesh A. Development of Yondelis (Trabectedin, 
ET-743). A semisynthetic process solves the supply problem. Nat Prod 
Rev. 2008;26(3):322–337.
 19. Moore II BM, Seaman FC, Hurley LH. NMR-based model of an ecteina-
scidin 743-DNA adduct. J Am Chem Soc. 1997;119(23):5475–5476.
 20. D’Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique 
mechanism of action. Mol Cancer Ther. 2010;9(8):2157–2163.
 21. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative 
activity of ecteinascidin 743 is dependent upon transcription-coupled 
nucleotide-excision repair. Nat Med. 2001;7(8):961–966.
 22. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), 
a natural marine compound, with a unique mechanism of action. Eur J 
Cancer. 2001;37(1):97–105.
 23. Tavecchio M, Simone M, Erba E, et al. Role of homologous 
recombination in trabectedin-induced DNA damage. Eur J Cancer. 
2008;44(4):609–618.
 24. Soares DG, Machado MS, Rocca CJ, et al. Trabectedin and its C 
subunit modified analogue PM01183 attenuate nucleotide excision 
repair and show activity toward platinum-resistant cells. Mol Cancer 
Ther. 2011;10(8):1481–1489.
 25. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity 
in different cellular systems with defined deficiencies in DNA-repair 
pathways. Int J Cancer. 2001;92(4):583–588.
 26. Schöffski P, Taron M, Jimeno J, et al. Predictive impact of DNA repair 
functionality on clinical outcome of advanced sarcoma patients treated 
with trabectedin: a retrospective multicentric study. Eur J Cancer. 
2011;47(7):1006–1012.
 27. Di Giandomenico S, Frapolli R, Bello E, et al. Mode of action of 
trabectedin in myxoid liposarcomas. Oncogene. 2013.
OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1283
Trabectedin in ovarian cancer
 28. Allavena P, Signorelli M, Chieppa M, et al. Anti-inflammatory 
properties of the novel antitumor agent yondelis (trabectedin): inhibition 
of macrophage differentiation and cytokine production. Cancer Res. 
2005;65(7):2964–2971.
 29. Germano G, Frapolli R, Simone M, et al. Antitumor and anti-
 inflammatory effects of trabectedin on human myxoid liposarcoma 
cells. Cancer Res. 2010;70(6):2235–2244.
 30. Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage 
targeting in the antitumor activity of trabectedin. Cancer Cell. 
2013;23(2):249–262.
 31. Perez-Ruixo JJ, Zannikos P, Hirankarn S, et al. Population 
 pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in 
cancer patients. Clin Pharmacokinet. 2007;46(10):867–884.
 32. Forouzesh B, Hidalgo M, Chu Q, et al. Phase I and pharmacokinetic 
study of trabectedin as a 1- or 3-hour infusion weekly in patients 
with advanced solid malignancies. Clin Cancer Res. 2009;15(10): 
3591–3599.
 33. van Kesteren C, Cvitkovic E, Taamma A, et al. Pharmacokinetics 
and pharmacodynamics of the novel marine-derived anticancer agent 
ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res. 
2000;6(12):4725–4732.
 34. van Kesteren C, Twelves C, Bowman A, et al. Clinical  pharmacology 
of the novel marine-derived anticancer agent Ecteinascidin 
743  administered as a 1- and 3-h infusion in a phase I study. Anticancer 
Drugs. 2002;13(4):381–393.
 35. Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic 
study of ecteinascidin-743, a new marine compound, administered as a 
24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 
2001;19(5):1256–1265.
 36. Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic 
study of ecteinascidin 743 administered as a 72-hour continuous 
intravenous infusion in patients with solid malignancies. Clin Cancer 
Res. 2001;7(2):231–242.
 37. Villalona-Calero MA, Eckhardt SG, Weiss G, et al. A phase I and 
pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in 
patients with solid malignancies. Clin Cancer Res. 2002;8(1): 75–85.
 38. Twelves C, Hoekman K, Bowman A, et al. Phase I and pharmacoki-
netic study of Yondelis (Ecteinascidin-743; ET-743) administered as an 
infusion over 1 h or 3 h every 21 days in patients with solid tumours. 
Eur J Cancer. 2003;39(13):1842–1851.
 39. Pardo B, Salazar R, Ciruelos E, et al. Phase I and pharmacokinetic 
study of trabectedin 3-hour infusion every three weeks in patients 
with advanced cancer and alteration of hepatic function. Med Oncol. 
2012;29(3):2240–2250.
 40. Brandon EF, Meijerman I, Klijn JS, et al. In-vitro cytotoxicity 
of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in 
the Hep G2 cell line: influence of cytochrome P450 and phase II 
inhibition, and cytochrome P450 induction. Anticancer Drugs. 
2005;16(9):935–943.
 41. Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, 
editors. Metabolic Drug Interactions. Philadelphia: Lippincott Williams 
and Wilkins, 2000.
 42. Reid JM, Kuffel MJ, Ruben SL, et al. Rat and human liver 
cytochrome P-450 isoform metabolism of ecteinascidin 743 does 
not predict gender-dependent toxicity in humans. Clin Cancer Res. 
2002;8(9):2952–2962.
 43. Beumer JH, Lopez-Lazaro L, Schellens JH, Beijnen JH, van Tellingen O. 
Evaluation of human plasma protein binding of trabectedin (Yondelis, 
ET-743). Curr Clin Pharmacol. 2009;4(1):38–42.
 44. Yondelis, INN-trabectedin – Europa [webpage on the Internet]. http://
www.ema.europa.eu/docs/it_IT/document./WC500045832.pdf.
 45. D’Incalci M, Colombo T, Ubezio P, et al. The combination of yondelis 
and cisplatin is synergistic against human tumor xenografts. Eur J 
Cancer. 2003;39(13):1920–1926.
 46. Sessa C, Cresta S, Noberasco C, et al. Phase I clinical and 
pharmacokinetic study of trabectedin and cisplatin in solid tumours. 
Eur J Cancer. 2009;45(12):2116–2122.
 47. Sessa C, Del Conte G, Christinat A, et al. Phase I clinical and 
pharmacokinetic study of trabectedin and cisplatin given every three 
weeks in patients with advanced solid tumors. Invest New Drugs. 
2013;31(5):1236–1243.
 48. Vidal L, Magem M, Barlow C, et al. Phase I clinical and 
pharmacokinetic study of trabectedin and carboplatin in patients with 
advanced solid tumors. Invest New Drugs. 2012;30(2):616–628.
 49. Meco D, Colombo T, Ubezio P, et al. Effective combination of ET-743 
and doxorubicin in sarcoma: preclinical studies. Cancer Chemother 
Pharmacol. 2003;52(2):131–138.
 50. von Mehren M, Schilder RJ, Cheng JD, et al. A phase I study of 
the safety and pharmacokinetics of trabectedin in combination with 
pegylated liposomal doxorubicin in patients with advanced 
malignancies. Ann Oncol. 2008;19(10):1802–1809.
 51. Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR. Sequence-
dependent enhancement of cytotoxicity produced by ecteinascidin 
743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma 
cells. Clin Cancer Res. 2001;7(10):3251–3257.
 52. Takahashi N, Li W, Banerjee D, et al. Sequence-dependent synergistic 
cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer 
cell lines in vitro and in vivo. Cancer Res. 2002;62(23): 6909–6915.
 53. Chu Q, Mita A, Forouzesh B, et al. Phase I and pharmacokinetic study 
of sequential paclitaxel and trabectedin every 2 weeks in patients with 
advanced solid tumors. Clin Cancer Res. 2010;16(9):2656–2665.
 54. Messersmith WA, Jimeno A, Ettinger D, et al. Phase I trial of weekly 
trabectedin (ET-743) and gemcitabine in patients with advanced solid 
tumors. Cancer Chemother Pharmacol. 2008;63(1):181–188.
 55. Gore L, Rivera E, Basche M, et al. Phase I combination study of 
trabectedin and capecitabine in patients with advanced malignancies. 
Invest New Drugs. 2012;30(5):1942–1949.
 56. Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with 
ovarian carcinoma after treatment with platinum and taxanes fails. 
J Clin Oncol. 2005;23(9):1867–1874.
 57. Krasner CN, McMeekin DS, Chan S, et al. A Phase II study of 
trabectedin single agent in patients with recurrent ovarian cancer 
previously treated with platinum-based regimens. Br J Cancer. 
2007;97(12):1618–1624.
 58. Del Campo JM, Roszak A, Bidzinski M, et al; Yondelis Ovarian Cancer 
Group. Phase II randomized study of trabectedin given as two different 
every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to 
patients with relapsed, platinum-sensitive, advanced ovarian cancer. 
Ann Oncol. 2009;20(11):1794–1802.
 59. del Campo JM, Sessa C, Krasner CN, et al. Trabectedin as single agent 
in relapsed advanced ovarian cancer: results from a retrospective pooled 
analysis of three phase II trials. Med Oncol. 2013;30(1):435.
 60. Ferrandina G, Salutari V, Vincenzi B, et al. Trabectedin as single agent 
in the salvage treatment of heavily treated ovarian cancer patients: a ret-
rospective, multicenter study. Gynecol Oncol. 2013;130(3): 505–510.
 61. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated 
liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 
2010;28(19):3107–3114.
 62. Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated 
liposomal doxorubicin in relapsed ovarian cancer: outcomes in the 
partially platinum-sensitive (platinum-free interval 6–12 months) 
subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 
2011;22(1):39–48.
 63. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated 
liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: 
overall survival analysis. Eur J Cancer. 2012;48(15):2361–2368.
 64. Kaye SB, Colombo N, Monk BJ, et al. Trabectedin plus pegylated 
liposomal doxorubicin in relapsed ovarian cancer delays third-line 
chemotherapy and prolongs the platinum-free interval. Ann Oncol. 
2011;22(1):49–58.
 65. Krasner CN, Poveda A, Herzog TJ, et al. Patient-reported outcomes in 
relapsed ovarian cancer: results from a randomized Phase III study of 
trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD 
alone. Gynecol Oncol. 2012;127(1):161–167.
OncoTargets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal
OncoTargets and Therapy is an international, peer-reviewed, open access 
journal focusing on the pathological basis of all cancers, potential 
targets for therapy and treatment protocols employed to improve the 
management of cancer patients. The journal also focuses on the impact 
of management programs and new therapeutic agents and protocols on 
patient perspectives such as quality of life, adherence and satisfaction. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
OncoTargets and Therapy 2014:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1284
Mascilini et al
 66. Fisher M, Gore M. Cost-effectiveness of trabectedin plus pegylated 
liposomal doxorubicin for the treatment of women with relapsed 
 platinum-sensitive ovarian cancer in the UK: analysis based on the 
final survival data of the OVA-301 trial. Value Health. 2013;16(4): 
507–516.
 67. Monk BJ, Kaye SB, Poveda A, et al. Nibrin is a marker of clinical 
outcome in patients with advanced serous ovarian cancer treated in the 
phase III OVA-301 trial. Gynecol Oncol. 2014;132(1):176–180.
